Sodium metaarsenite - Komipharm International

Drug Profile

Sodium metaarsenite - Komipharm International

Alternative Names: KML 001; KOMINOX

Latest Information Update: 10 Jun 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Komipharm International
  • Developer Komipharm International; University of Maryland Greenbaum Cancer Center
  • Class Antineoplastics; Arsenicals
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cholangiocarcinoma; Hepatocellular carcinoma; Lung cancer; Non-Hodgkin's lymphoma; Prostate cancer
  • Phase I Non-small cell lung cancer

Most Recent Events

  • 09 Jun 2016 Chemical structure information added
  • 09 Jun 2016 Discontinued - Phase-II for Prostate cancer in Germany (PO)
  • 09 Jun 2016 Phase-I clinical trials in Prostate cancer in Germany (PO) before June 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top